Saturday 7 November 2026 Export MTNB’s income statement to Excel — free account

Matinas Biopharma Holdings, Inc.

Matinas Biopharma Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.1 million, down 65.6% from fiscal 2022.

EPS: +79.6%
Free cash flow: +9.15%
Total debt: −54.5%

Quarter to June 2026, against a year earlier

1.25 0.09 +7.76%

Follow MTNB

Alert me

Market cap: $1.1M
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: 1/9
Altman Z: −7.44
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 1.14

Revenue ttm 4.28

Net income ttm (6.69)

Free cash flow ttm (6.42)

Net debt Q (0.81)

Valuation

P/E 0.00

Forward P/E (0.13)

Price / sales 0.12

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.30

Financial health

Current ratio Q 0.85

Debt / equity Q 0.00

Interest coverage Q —

Growth

Revenue growth Q 0.00%

Operating income growth Q +15.35%

EPS, this year +26.18%

EPS, next year A +63.05%

Revenue, next year A +0.18%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.15%

10-year low 10-year high

P/B against its own 10 years 2.57%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	14	7	4	1
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	16	8	4	1

	2023	2024	2025	Q'26
Payables	1	0	0	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	3	3	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	55.69%	90.59%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(2.26%)	(40.31%)	(49.10%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY23 Estimate −22.49 Actual −22.49

−23.61 −21.18 −18.74 −16.30 −13.86

Q2 FY22 Met 0.00

Q3 FY22 Met 0.00

Q4 FY22 Met 0.00

Q1 FY23 Met 0.00

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY22	−22.49	−22.49	Met by 0.00
Q3 FY22	−22.49	−22.49	Met by 0.00
Q4 FY22	−14.99	−14.99	Met by 0.00
Q1 FY23	−22.49	−22.49	Met by 0.00

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(4.50)	(3.15)	—	—	—
’25	(4.95)	(15.44)	(6.00)	(3.90)	(29.98)
’24	(22.49)	(14.99)	(12.74)	(25.19)	(74.66)
’23	(22.49)	(22.49)	(22.49)	(22.49)	(82.46)
’22	(22.49)	(22.49)	(22.49)	(14.99)	(74.96)
’21	(22.49)	(14.99)	(22.49)	(22.49)	(82.46)
’20	(22.49)	(22.49)	(22.49)	(22.49)	(89.95)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’23	1	—	—	—	1
’22	—	1	1	1	3
’21	0	—	—	0	0
’20	—	—	0	0	0
’19	—	0	—	—	0
’18	0	0	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	(2)	(1)	(2)	(7)
’24	(6)	(3)	(3)	(4)	(16)
’23	(4)	(2)	(4)	(5)	(15)
’22	(5)	(5)	(5)	(4)	(19)
’21	(5)	(1)	(6)	(4)	(15)
’20	(5)	(3)	(5)	(4)	(17)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	(2)	(1)	(1)	(7)
’24	(6)	(3)	(3)	(4)	(16)
’23	(4)	(2)	(4)	(5)	(15)
’22	(5)	(5)	(5)	(4)	(20)
’21	(5)	(1)	(6)	(4)	(15)
’20	(5)	(3)	(5)	(4)	(17)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	0	0	0	0	0	3	1	—	—	4		+39.3%	—	—	—	—
	Gross margin, %	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	—	—	0.00		+100.0 pt	Powerpack Matinas Biopharma Holdings, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(8)	(16)	(15)	(17)	(22)	(23)	(21)	(23)	(24)	(10)	(7)		+3.5%
	EBT margin, %	0.00	(10,583.43)	(12,178.63)	(19,345.99)	(14,179.91)	(70,554.55)	(658.63)	(2,093.25)	0.00	0.00	0.00		0.0 pt
	Net income	(8)	(15)	(14)	(17)	(22)	(23)	(21)	(23)	(24)	(10)	(7)		+3.5%
Per share, $
Per share, $	Revenue	0.00	1.24	0.92	0.46	0.60	0.12	11.02	3.78	0.00	0.00	0.00		n/m
	Earnings	(157.42)	(269.87)	(112.44)	(97.45)	(89.95)	(82.46)	(74.96)	(82.46)	(74.66)	(29.98)	(17.54)		(16.8%)
	Cash flow	(79.57)	(94.94)	(78.85)	(72.75)	(66.11)	(54.29)	(66.24)	(52.72)	(48.94)	(19.20)	(15.02)		(14.6%)
	Capex	0.00	(7.81)	(4.09)	(2.09)	(0.02)	(0.93)	(3.08)	(0.75)	0.00	0.92	0.00		n/m
	Free cash flow	(79.57)	(102.75)	(82.94)	(74.85)	(66.13)	(55.22)	(69.32)	(53.47)	(48.94)	(18.29)	(15.02)		(15.1%)
	Book value	92.98	88.50	123.31	170.63	242.60	187.21	126.68	66.41	23.38	13.23	4.21		(19.5%)
	Shares, m	0	0	0	0	0	0	0	0	0	0	0		+18.9%
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	0.00		0.0
	P/S	—	749.80	278.81	1,296.21	792.96	1,108.52	36.26	11.41	—	—	0.12		610.6
	P/B	—	22.61	9.18	11.35	4.47	4.05	3.16	2.54	—	—	0.30		8.2
	EV/Sales	—	700.41	219.44	1,186.27	618.97	849.28	27.23	8.20	—	—	(0.06)		515.7
	EV/FCF	—	(8.44)	(4.23)	(20.82)	(12.04)	(10.51)	(4.33)	(2.26)	—	—	0.04		(8.9)
Cash, $m
Cash, $m	Operating cash flow	(6)	(11)	(10)	(14)	(17)	(15)	(19)	(15)	(16)	(7)	(6)		+1.5%
	Capex	—	(1)	(1)	0	0	0	(1)	0	—	0	0		n/m
	Free cash flow	(6)	(12)	(11)	(14)	(17)	(15)	(20)	(15)	(16)	(7)	(6)		+1.0%
Balance, $m
Balance, $m	Working capital	3	6	10	27	58	47	30	13	5	3	0		(2.0%)
	Net debt	(4)	(7)	(12)	(28)	(59)	(50)	(29)	(14)	(7)	(4)	(1)		(0.5%)
	Shareholders’ equity	7	11	16	33	64	52	37	19	8	5	2		(4.3%)
Returns, %
Returns, %	ROA	(131.62)	(270.93)	(87.22)	(60.80)	(41.80)	(35.80)	(39.56)	(65.62)	(128.50)	(110.46)	(98.53)		+21.2 pt
	ROIC	(177.63)	(313.71)	(247.23)	(232.74)	(306.30)	(547.23)	(195.88)	(272.15)	(5,735.31)	(553.44)	(419.27)		(375.8) pt
	ROE	(336.12)	(1,089.33)	(264.65)	(103.29)	(52.23)	(42.12)	(47.11)	(82.11)	(180.73)	(176.54)	(154.28)		+159.6 pt
People
People	Employees	10	15	15	21	20	31	34	32	3	2	—		(16.4%)
	Revenue/emp, $m	0.00	0.01	0.01	0.00	0.01	0.00	0.09	0.03	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2023 · latest quarter Mar 2023 · fundamentals updated 2 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ELAB PMGC Holdings Inc.	$1.3M	— (loss-making)	—	+147.70% (above 0%: growing)	n/m	−44.95% (below 0%: shrinking)	29.52%	(292.91%)	Compare
LABT Lakewood-Amedex Biotherapeutics Inc.	$1.3M	— (loss-making)	—	—	n/m	−420.66% (below 0%: shrinking)	—	0.00%	Compare
PTIX Atrinsic Inc.	$1.3M	0.2×	—	+34.31% (above 0%: growing)	n/m	+46.07% (above 0%: growing)	0.00%	0.00%	Compare
BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR	$1.3M	— (loss-making)	—	−32.27% (below 0%: shrinking)	+96.36% (above 0%: growing)	−0.17% (below 0%: shrinking)	0.00%	0.00%	Compare
ARTL Artelo Biosciences, Inc.	$1.2M	— (loss-making)	—	—	n/m	−879.18% (below 0%: shrinking)	0.00%	0.00%	Compare
MTNB Matinas Biopharma Holdings, Inc.	$1.1M	— (loss-making)	— (loss-making)	0.00%	n/m	+9.15% (above 0%: growing)	0.00%	0.00%
BBLG Bone Biologics Corp.	$1.1M	— (loss-making)	—	—	n/m	+9.99% (above 0%: growing)	—	0.00%	Compare
VBIO Valion Bio, Inc.	$1.1M	— (loss-making)	— (loss-making)	+15.87% (above 0%: growing)	n/m	−189.01% (below 0%: shrinking)	(99.32%)	0.00%	Compare
BPTH Bio-Path Holdings, Inc.	$1.1M	— (loss-making)	— (loss-making)	—	n/m	+98.68% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$1.2M	—	—	+25.09%	—	−22.56%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 12 May 2025

Ownership

Directors and executive officers, together 4.60%

Sanitam Partners LLC 9.99%

Highbridge Capital Management, LLC 8.40%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Matinas Biopharma Holdings, Inc. (MTNB) Latest News

4 Sep

Impact 4 · 5:00 PM

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

13 Jul

Impact 5 · 8:00 AM

Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals

Impact 4 · 3:45 PM

GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma

3 Apr

Impact 4 · 5:00 PM · GlobeNewswire

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Impact 4 · 8:30 AM · GlobeNewswire

Matinas BioPharma Prices $10 Million Registered Direct Offering

23 Sep

Impact 4 · 7:22 PM · Insider Monkey

Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203

11 Mar

Impact 4 · 7:00 AM · GlobeNewswire

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

13 Feb

Impact 4 · 5:00 PM · GlobeNewswire

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

7 Feb

Impact 3 · 7:30 AM · GlobeNewswire

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

31 Oct

Impact 4 · 6:30 AM · GlobeNewswire

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

14 Aug

Impact 4 · 4:05 PM · GlobeNewswire

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

7 Aug

Impact 3 · 7:00 AM · GlobeNewswire

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

24 Jun

Impact 4 · 8:30 AM · GlobeNewswire

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

13 Jun

Impact 4 · 7:00 AM · GlobeNewswire

Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

16 May

Impact 4 · 7:00 AM · GlobeNewswire

New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

10 May

Impact 4 · 1:22 PM · Thomson Reuters StreetEvents

Q1 2024 Matinas BioPharma Holdings Inc Earnings Call

Impact 4 · 12:46 PM · Insider Monkey

Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call Transcript

9 May

Impact 4 · 4:05 PM · GlobeNewswire

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

7 May

Impact 4 · 8:00 AM · GlobeNewswire

Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting

2 May

Impact 4 · 7:00 AM · GlobeNewswire

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

30 Apr

Impact 4 · 8:00 AM · GlobeNewswire

In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

1 Apr

Impact 4 · 2:24 PM · Insider Monkey

Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript

28 Mar

Impact 4 · 6:46 AM · Thomson Reuters StreetEvents

Q4 2023 Matinas BioPharma Holdings Inc Earnings Call

27 Mar

Impact 4 · 4:05 PM · GlobeNewswire

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

25 Mar

Impact 4 · 8:00 AM · GlobeNewswire

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

22 Mar

Impact 4 · 12:37 PM · Benzinga

Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?

Impact 4 · 9:15 AM · GlobeNewswire

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

26 Feb

Impact 4 · 8:00 AM · GlobeNewswire

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

20 Feb

Impact 4 · 7:30 AM · GlobeNewswire

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

3 Jan

Impact 4 · 7:00 AM · GlobeNewswire

Matinas BioPharma to Present at Biotech Showcase 2024

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Matinas Biopharma Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 12 May 2025

Ownership

Matinas Biopharma Holdings, Inc. (MTNB) Latest News

4 Sep

13 Jul

3 Apr

23 Sep

11 Mar

13 Feb

7 Feb

31 Oct

14 Aug

7 Aug

24 Jun

13 Jun

16 May

10 May

9 May

7 May

2 May

30 Apr

1 Apr

28 Mar

27 Mar

25 Mar

22 Mar

26 Feb

20 Feb

3 Jan

Stockrow Weekly